专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

51. 发明申请

US20080249038A1 Bone Morphogenetic Protein (Bmp) 2A and Uses Thereof 审中-公开
标题翻译：骨形态发生蛋白（Bmp）2A及其用途
公开(公告)号：US20080249038A1
公开(公告)日：2008-10-09
申请号：US10575121
申请日：2004-10-06
申请人： Elena Feinstein , Igor Mett , Svetlana Gorodin , Michael Shtutman
发明人： Elena Feinstein , Igor Mett , Svetlana Gorodin , Michael Shtutman
IPC分类号： A61K31/7088 , C07H21/04 , C12N15/00
CPC分类号： C12N15/1136 , C12N2310/11 , C12N2310/111 , C12N2310/14
摘要： The present invention provides compositions and methods for alleviation or reduction of the symptoms and signs associated with damaged neuronal tissues whether resulting from tissue trauma, or from chronic or acute degenerative changes. In particular, some embodiments of the present invention provide one or more pharmaceutical compositions comprising as an active ingredient a BMP2A inhibitor further comprising a pharmaceutically acceptable diluent or carrier. An additional embodiment provides a method for reducing damage to the central nervous system in a patient who has suffered an injury to the central nervous system, comprising administering to the patient a pharmaceutical composition in a dosage sufficient to reduce the damage. Yet another embodiment provides of the use of a BMP2A inhibitor for the preparation of a medicament for promoting or enhancing recovery in a patient who has suffered an injury to the central nervous system. Preferable inhibitors according to some embodiments of the invention are siRNA molecules and neutralizing antibodies. An additional embodiment provides a method for identifying a chemical compound that modulates apoptosis. Further, a process for diagnosing a neurodegenerative disease or an ischemic event in a subject is provided. The preferred methods, materials, and examples that will now be described are illustrative only and are not intended to be limiting; materials and methods similar or equivalent to those described herein can be used in practice or testing of the invention. Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.
摘要翻译：本发明提供用于缓解或减少与损伤的神经元组织相关的症状和体征的组合物和方法，无论是由组织创伤引起的，还是由慢性或急性退行性变化引起。特别地，本发明的一些实施方案提供一种或多种药物组合物，其包含作为活性成分的进一步包含药学上可接受的稀释剂或载体的BMP2A抑制剂。另一个实施方案提供了减轻对中枢神经系统损伤的患者中的中枢神经系统的损伤的方法，包括以足以减少损伤的剂量向患者施用药物组合物。另一个实施方案提供了BMP2A抑制剂用于制备用于促进或增强患有中枢神经系统损伤的患者的恢复的药物的用途。根据本发明一些实施方案的优选的抑制剂是siRNA分子和中和抗体。另外的实施方案提供了鉴定调节细胞凋亡的化合物的方法。此外，提供了用于诊断受试者中的神经变性疾病或缺血事件的方法。现在将要描述的优选方法，材料和实施例仅是说明性的而不是限制性的; 可以在本发明的实践或测试中使用与本文所述类似或等同的材料和方法。从以下详细描述和权利要求书中，本发明的其它特征和优点将变得显而易见。

52. 发明授权

US09056903B2 Therapeutic uses of inhibitors of RTP801 有权
标题翻译： RTP801抑制剂的治疗用途
公开(公告)号：US09056903B2
公开(公告)日：2015-06-16
申请号：US13233907
申请日：2011-09-15
申请人： Elena Feinstein , Rami Skaliter
发明人： Elena Feinstein , Rami Skaliter
IPC分类号： C12N15/113 , C07K16/18 , C07K14/47 , C07K16/22 , A61K39/00
CPC分类号： C07K16/18 , A61K2039/505 , C07K14/4747 , C07K16/22 , C12N15/113 , C12N2310/14 , C12N2310/321 , C12N2310/3521
摘要： The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases respiratory conditions and hearing disorders based upon inhibition of the RTP801 gene and/or protein.
摘要翻译：本发明提供了基于RTP801基因和/或蛋白质的抑制来治疗微血管病症，眼部疾病呼吸系统疾病和听力障碍的新型分子，组合物，方法和用途。

53. 发明授权

US08765699B2 Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases 有权
标题翻译：寡核糖核苷酸及其用于治疗脱发，急性肾衰竭和其它疾病的方法
公开(公告)号：US08765699B2
公开(公告)日：2014-07-01
申请号：US11237598
申请日：2005-09-27
申请人： Elena Feinstein , Daniel Zurr , Shai Ehrlich
发明人： Elena Feinstein , Daniel Zurr , Shai Ehrlich
IPC分类号： C12N15/113
CPC分类号： C12N15/1135 , C07H21/02 , C12N15/113 , C12N2310/14 , C12N2320/30
摘要： The invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of a human p53 gene. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient suffering from alopecia or acute renal failure or other diseases comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient. The alopecia may be induced by chemotherapy or radiotherapy, and the patient may be suffering from cancer, in particular breast cancer.
摘要翻译：本发明涉及下调人p53基因表达的双链化合物，优选寡核糖核苷酸。本发明还涉及包含该化合物或能够表达寡核糖核苷酸化合物的载体和药学上可接受的载体的药物组合物。本发明还考虑了治疗患有脱发或急性肾功能衰竭或其它疾病的患者的方法，包括以治疗有效剂量向患者施用药物组合物，从而治疗患者。秃发可以通过化学疗法或放射疗法诱发，患者可能患有癌症，特别是乳腺癌。

54. 发明授权

US08444983B2 Composition of anti-ENDO180 antibodies and methods of use for the treatment of cancer and fibrotic diseases 有权
标题翻译：抗ENDO180抗体的组成和用于治疗癌症和纤维化疾病的方法
公开(公告)号：US08444983B2
公开(公告)日：2013-05-21
申请号：US13255214
申请日：2010-03-23
申请人： Elena Feinstein
发明人： Elena Feinstein
IPC分类号： A61K51/10 , A61K49/16 , A61K39/395 , A61K39/44
CPC分类号： A61K47/6849 , A61K39/39541 , A61K39/39558 , A61K49/0058 , C07K16/2851 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/77 , C07K2317/92
摘要： The present invention provides antibodies or antigen-binding fragments thereof that specifically bind the ENDO180 polypeptide and are internalized thereby, to conjugates comprising the molecules, to compositions comprising the antibodies and conjugates and to methods of using the same for delivery of therapeutic agents to cells that express the ENDO180 polypeptide on the surface of the cell for treating cell proliferative diseases or disorders and fibrosis, and for controlling (modulating) tumor progression.
摘要翻译：本发明提供了特异性结合ENDO180多肽并由此被内化至包含该分子的缀合物的抗体或其抗原结合片段与包含抗体和缀合物的组合物，以及使用该抗体或缀合物的方法将治疗剂递送至细胞在细胞表面表达ENDO180多肽，用于治疗细胞增殖性疾病或病症和纤维化，并控制（调节）肿瘤进展。

55. 发明授权

US08309532B2 Therapeutic uses of inhibitors of RTP801 有权
标题翻译： RTP801抑制剂的治疗用途
公开(公告)号：US08309532B2
公开(公告)日：2012-11-13
申请号：US12803118
申请日：2010-06-17
申请人： Elena Feinstein , Jorg Kaufmann , Klaus Giese
发明人： Elena Feinstein , Jorg Kaufmann , Klaus Giese
IPC分类号： A61K31/70 , C07H21/02 , C07H21/04
CPC分类号： C07H21/02 , A01K2217/058 , A01K2267/0362 , A61K31/713 , A61K39/39541 , A61K45/06 , C12N15/113 , C12N2310/14 , C12N2310/321 , A61K2300/00 , C12N2310/3521
摘要： The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases and respiratory conditions based upon inhibition of the RTP801 gene and/or protein.
摘要翻译：本发明提供了基于RTP801基因和/或蛋白质的抑制来治疗微血管病症，眼部疾病和呼吸病症的新型分子，组合物，方法和用途。

56. 发明授权

US08198258B2 Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases 有权
标题翻译：寡核糖核苷酸及其用于治疗纤维化病症和其它疾病的方法
公开(公告)号：US08198258B2
公开(公告)日：2012-06-12
申请号：US13092501
申请日：2011-04-22
申请人： Orna Mor , Elena Feinstein
发明人： Orna Mor , Elena Feinstein
IPC分类号： A61K31/70 , C07H21/02 , C07H21/04 , C12Q1/68
CPC分类号： C07H21/04 , C07K16/40 , C07K2317/21 , C07K2317/76 , C12N9/1044 , C12N15/1137 , C12N2310/111 , C12N2310/14 , C12N2310/321 , C12N2310/322 , C12Y203/02013 , C12N2310/3527 , C12N2310/3521
摘要： The invention relates to a double-stranded compound, preferably an oligoribonucleotide (siRNA), which down-regulates the expression of a human TGaseII gene at the post-transcriptional level. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient suffering from a fibrotic disease such as pulmonary, kidney and liver fibrosis or ocular, scarring comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient. The invention also relates to treatment of fibrotic and other diseases by use of antibodies to TGaseII polypeptide.
摘要翻译：本发明涉及在转录后水平下调人TGaseII基因表达的双链化合物，优选寡核糖核苷酸（siRNA）。本发明还涉及包含该化合物或能够表达寡核糖核苷酸化合物的载体和药学上可接受的载体的药物组合物。本发明还考虑了治疗患有纤维化疾病如肺，肾和肝纤维化或眼睛，瘢痕形成的患者的方法，其包括以治疗有效剂量向患者施用药物组合物，从而治疗患者。本发明还涉及通过使用TGaseII多肽的抗体来治疗纤维化和其它疾病。

57. 发明申请

US20110117102A1 Therapeutic uses of inhibitors of RTP801 有权
标题翻译： RTP801抑制剂的治疗用途
公开(公告)号：US20110117102A1
公开(公告)日：2011-05-19
申请号：US12803118
申请日：2010-06-17
申请人： Elena Feinstein , Jorg Kaufmann , Klaus Giese
发明人： Elena Feinstein , Jorg Kaufmann , Klaus Giese
IPC分类号： A61K39/395 , A61K31/7088 , C07H21/02 , A61P27/06 , A61P11/00 , A61P27/02
CPC分类号： C07H21/02 , A01K2217/058 , A01K2267/0362 , A61K31/713 , A61K39/39541 , A61K45/06 , C12N15/113 , C12N2310/14 , C12N2310/321 , A61K2300/00 , C12N2310/3521
摘要： The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases and respiratory conditions based upon inhibition of the RTP801 gene and/or protein.
摘要翻译：本发明提供了基于RTP801基因和/或蛋白质的抑制来治疗微血管病症，眼部疾病和呼吸病症的新型分子，组合物，方法和用途。

58. 发明授权

US07910566B2 Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA 有权
标题翻译：通过siRNA抑制p53，预防和治疗急性肾功能衰竭等肾脏疾病
公开(公告)号：US07910566B2
公开(公告)日：2011-03-22
申请号：US12006722
申请日：2008-01-04
申请人： Elena Feinstein
发明人： Elena Feinstein
IPC分类号： A61K48/00 , C07H21/02 , C07H21/04
CPC分类号： A61K31/70
摘要： The invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of a human p53 gene. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient suffering from acute renal failure or other kidney diseases comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient.
摘要翻译：本发明涉及下调人p53基因表达的双链化合物，优选寡核糖核苷酸。本发明还涉及包含该化合物或能够表达寡核糖核苷酸化合物的载体和药学上可接受的载体的药物组合物。本发明还考虑了治疗患有急性肾衰竭或其它肾脏疾病的患者的方法，包括以治疗有效剂量向患者施用药物组合物，从而治疗患者。

59. 发明申请

US20090202566A1 Use of the ENDO-180 gene and polypeptide for diagnosis and treatment 审中-公开
标题翻译：使用ENDO-180基因和多肽进行诊断和治疗
公开(公告)号：US20090202566A1
公开(公告)日：2009-08-13
申请号：US12317231
申请日：2008-12-19
申请人： Orna Mor , Elena Feinstein , Alexander Faerman
发明人： Orna Mor , Elena Feinstein , Alexander Faerman
IPC分类号： A61K39/395 , C12N5/00 , A61K31/7052 , A61P35/00 , A61P19/02 , A61P3/00 , A61P13/12 , A61P9/00
CPC分类号： G01N33/5032 , G01N33/6872 , G01N2333/4724 , G01N2333/78
摘要： This application is directed to a process of identifying a compound capable of modulating activity of a human ENDO180 receptor that comprises the steps of measuring the binding of the ENDO180 receptor to an interactor with which the ENDO180 receptor interacts specifically in vivo, in the absence or presence of a compound, and determining whether the binding of the ENDO180 receptor to the interactor is affected by the compound. This application is also directed to use of a compound identified by that process in the preparation of a medicament for therapy of disease, in particular fibrosis. This application also relates to the use of ENDO180 modulators in treatment of disease.
摘要翻译：本申请涉及鉴定能够调节人ENDO180受体活性的化合物的方法，该方法包括以下步骤：在不存在或存在下测量ENDO180受体与ENDO180受体在体内特异性相互作用的相互作用因子的结合的化合物，并确定ENDO180受体与相互作用体的结合是否受化合物的影响。本申请还涉及通过该方法鉴定的化合物在制备用于治疗疾病，特别是纤维化的药物中的用途。本申请还涉及使用ENDO180调节剂治疗疾病。

60. 发明申请

US20080293655A1 Novel tandem siRNAS 有权
标题翻译：新型串联siRNAS
公开(公告)号：US20080293655A1
公开(公告)日：2008-11-27
申请号：US11704600
申请日：2007-02-08
申请人： Huseyin Aygun , Elena Feinstein
发明人： Huseyin Aygun , Elena Feinstein
IPC分类号： A61K31/7105 , C07H21/02 , C12N15/63
CPC分类号： C12N15/111 , C12N2310/14 , C12N2310/315 , C12N2310/318 , C12N2310/321 , C12N2310/51 , C12N2310/52 , C12N2310/3521
摘要： The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases and respiratory conditions based upon inhibition of two or more target genes.
摘要翻译：本发明提供了基于两种或更多种靶基因的抑制来治疗微血管病症，眼睛疾病和呼吸病症的新型分子，组合物，方法和用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式